User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Blocking the cannabinoid receptors: Drug candidates and therapeutic promises

Primary tabs

Muccioli, Giulio [UCL]

The CB1 and CB2 cannabinoid receptors have been described as two prime sites of action for endocannabinoids. Both the localization and pharmacology of these two G-protem-coupled receptors are well-described, and numerous selective ligands have been characterized. The physiological effects of Cannabis sativa (cannabis) and a throughout study of the endocannabinoid system allowed for the identification of several pathophysiological conditions - including obesity, dyslipidemia, addictions, inflammation. and allergies - in which blocking the cannabinoid receptors might be beneficial. Many CB, receptor antagonists are now in clinical trials, and the results of several studies involving the CB, antagonist lead compound rimonabant (SR141716A) are now available. This review describes the pharmacological tools that are currently available and the animal studies supporting the therapeutic use of cannabinoid receptor antagonists and inverse agonists. The data available from the clinical trials are also discussed.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès restreint
Publication date 2007
Language Anglais
Journal information "Chemistry & Biodiversity" - Vol. 4, no. 8, p. 1805-1827 (2007)
Peer reviewed yes
Publisher Wiley-v C H Verlag Gmbh (Weinheim)
issn 1612-1872
e-issn 1612-1880
Publication status Publié
Affiliation UCL - MD/FARM - Ecole de pharmacie
Links
  1. Ledent, Science, 283, 401 (1999)
  2. Zimmer, Proc. Natl. Acad. Sci. U.S.A, 96, 5780 (1999)
  3. Buckley, Eur. J. Pharmacol., 396, 141 (2000)
  4. Matsuda, Nature, 346, 561 (1990)
  5. Munro, Nature, 365, 61 (1993)
  6. Jarai, Proc. Natl. Acad. Sci. U.S.A, 96, 14136 (1999)
  7. Marzo, Nature, 410, 822 (2001)
  8. Cota, J. Clin. Invest., 112, 423 (2003)
  9. Cossu, Behav. Brain Res., 118, 61 (2001)
  10. Martin, Eur. J. Neurosci., 12, 4038 (2000)
  11. Rinaldi-Carmona, FEBS Lett., 350, 240 (1994)
  12. Rinaldi-Carmona, J. Pharmacol. Exp. Ther., 284, 644 (1998)
  13. Rinaldi-Carmona, Life Sci., 56, 1941 (1995)
  14. Pertwee, Life Sci., 76, 1307 (2005)
  15. Hurst, Mol. Pharmacol., 62, 1274 (2002)
  16. Salo, J. Med. Chem., 47, 3048 (2004)
  17. Hurst, J. Med. Chem., 49, 5969 (2006)
  18. McAllister, J. Biol. Chem., 279, 48024 (2004)
  19. Reggio, Curr. Pharm. Des., 9, 1607 (2003)
  20. Gatley, Eur. J. Pharmacol., 307, 331 (1996)
  21. Lan, J. Med. Chem., 42, 769 (1999)
  22. Hajos, Neuroscience, 106, 1 (2001)
  23. Hajos, Neuropharmacology, 43, 503 (2002)
  24. Haller, Eur. J. Neurosci., 16, 1395 (2002)
  25. Haller, Behav. Pharmacol., 15, 299 (2004)
  26. Mackie, AAPS J., 8 (2006)
  27. Rinaldi-Carmona, J. Pharmacol. Exp. Ther., 310, 905 (2004)
  28. Gessa, Alcohol Alcoholism, 40, 46 (2005)
  29. Pamplona, Neurosci. Lett., 397, 88 (2006)
  30. Lallemand, Alcohol, 39, 125 (2006)
  31. Thomas, AAPS J., 8 (2006)
  32. Lange, Drug Discov. Today, 10, 693 (2005)
  33. Muccioli, Expert Opin. Ther. Pat., 16, 1405 (2006)
  34. Carpino, Bioorg. Med. Chem. Lett., 16, 731 (2006)
  35. Murineddu, J. Med. Chem., 48, 7351 (2005)
  36. Ruiu, J. Pharmacol. Exp. Ther., 306, 363 (2003)
  37. Stoit, Chem. Pharm. Bull., 50, 1109 (2002)
  38. Dyck, Bioorg. Med. Chem. Lett., 14, 1151 (2004)
  39. Lange, J. Med. Chem., 48, 1823 (2005)
  40. Jagerovic, J. Med. Chem., 47, 2939 (2004)
  41. Bass, Pharmacol. Biochem. Behav., 74, 31 (2002)
  42. Meurer, Bioorg. Med. Chem. Lett., 15, 645 (2005)
  43. Madsen-Duggan, Bioorg. Med. Chem. Lett., 17, 2031 (2007)
  44. Plummer, Bioorg. Med. Chem. Lett., 15, 1441 (2005)
  45. Debenham, Bioorg. Med. Chem. Lett., 16, 681 (2006)
  46. Lange, J. Med. Chem., 47, 627 (2004)
  47. Lange, Bioorg. Med. Chem. Lett., 15, 4794 (2005)
  48. Muccioli, J. Med. Chem., 48, 7486 (2005)
  49. Lin, J. Med. Chem., 49, 7584 (2006)
  50. Carai, Life Sci., 77, 2339 (2005)
  51. Mackie, Annu. Rev. Pharmacol., 46, 101 (2006)
  52. Meltzer, Am. J. Psychiatry, 161, 975 (2004)
  53. Arnone, Psychopharmacology (Berlin), 132, 104 (1997)
  54. Simiand, Behav. Pharmacol., 9, 179 (1998)
  55. Colombo, Life Sci., 63 (1998)
  56. Need, Psychopharmacology (Berlin), 184, 26 (2006)
  57. Chambers, Physiol. Behav., 82, 863 (2004)
  58. Pavon, Neuropharmacology, 51, 358 (2006)
  59. Bensaid, Mol. Pharmacol., 63, 908 (2003)
  60. Vickers, Psychopharmacology, 167, 103 (2003)
  61. Ravinet, Am. J. Physiol., Reg. Integr. Comp. Physiol., 284 (2003)
  62. Hildebrandt, Eur. J. Pharmacol., 462, 125 (2003)
  63. COLOMBO G., AGABIO R., FA M., GUANO L., LOCHE A., REALI R., GESSA G. L., REDUCTION OF VOLUNTARY ETHANOL INTAKE IN ETHANOL-PREFERRING sP RATS BY THE CANNABINOID ANTAGONIST SR-141716, 10.1093/oxfordjournals.alcalc.a008368
  64. Gallate, Psychopharmacology, 142, 302 (1999)
  65. Vinklerova, J. Psychopharmacol., 16, 139 (2002)
  66. Navarro, J. Neurosci., 21, 5344 (2001)
  67. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrié P., SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats : , 10.1097/00008877-200209000-00018
  68. Cohen, Neuropsychopharmacology, 30, 145 (2005)
  69. Terranova, Psychopharmacology, 126, 165 (1996)
  70. Lichtman, Eur. J. Pharmacol., 404, 175 (2000)
  71. Wolff, Eur. J. Pharmacol., 477, 213 (2003)
  72. Rodgers, Behav. Pharmacol., 16, 405 (2005)
  73. Patel, Neuropsychopharmacology, 30, 497 (2005)
  74. Shearman, Behav. Pharmacol., 14, 573 (2003)
  75. Martin, Psychopharmacology, 165, 128 (2003)
  76. Segovia, Mov. Disord., 18, 138 (2003)
  77. Gonzalez, Brain Res., 1073–1074, 209 (2006)
  78. Gessa, Eur. J. Pharmacol., 327 (1997)
  79. Gessa, Eur. J. Pharmacol., 355, 119 (1998)
  80. Degroot, Mol. Pharmacol, 70, 1236 (2006)
  81. Tzavara, J. Neurosci., 23, 9374 (2003)
  82. Melis, Neurosci. Lett., 359, 17 (2004)
  83. Teixeira-Clerc, Nat. Med., 12, 671 (2006)
  84. Croci, Br. J. Pharmacol., 140, 115 (2003)
  85. Costa, Pain, 116, 52 (2005)
  86. Croci, Br. J. Pharmacol., 150, 559 (2007)
  87. Freedland, Pharmacol. Biochem. Behav., 67, 265 (2000)
  88. Verty, Neurosci. Lett., 354, 217 (2004)
  89. McLaughlin, Behav. Pharmacol., 14, 583 (2003)
  90. Ravinet-Trillou, Int. J. Obes., 28, 640 (2004)
  91. Werner, Brain Res., 967, 290 (2003)
  92. Williams, Pharmacol. Biochem. Behav., 71, 333 (2002)
  93. Pacher, Pharmacol Rev., 58, 389 (2006)
  94. Pagotto, Int. J. Obes., 30 (2006)
  95. , , , , to Neurogen Corp. (U.S.A.), WO2005094305, 2005.
  96. Gamber Kevin M., Macarthur Heather, Westfall Thomas C., Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus, 10.1016/j.neuropharm.2005.04.017
  97. Massi, J. Pharmacol. Exp. Ther., 308, 838 (2004)
  98. Tucci, Br. J. Pharmacol., 143, 520 (2004)
  99. Rigamonti, Eur. J. Pharmacol., 542, 116 (2006)
  100. Hilairet, J. Biol. Chem., 278, 23731 (2003)
  101. Ellis, J. Biol. Chem., 281, 38812 (2006)
  102. Kirkham, Psychopharmacology, 153, 267 (2001)
  103. Justinova, J. Neurosci., 25, 5645 (2005)
  104. Hermann, Neurosci. Lett., 375, 13 (2005)
  105. Verty, Endocrinology, 145, 3224 (2004)
  106. Osei-Hyiaman, Neuroendocrinology, 81, 273 (2005)
  107. Osei-Hyiaman, J. Clin. Invest., 115, 1298 (2005)
  108. Doyon, Diabetes, 55, 3403 (2006)
  109. Poirier, Diabetes Obes. Metab., 7, 65 (2005)
  110. Jbilo, FASEB J., 19, 1567 (2005)
  111. Gary-Bobo, Mol. Pharmacol., 69, 471 (2006)
  112. Hu, Proc. Natl. Acad. Sci. U.S.A, 102, 3972 (2005)
  113. Loftus, Science, 288, 2379 (2000)
  114. Gelfand, J. Am. Coll. Cardiol., 47, 1919 (2006)
  115. Engeli, Diabetes, 54, 2838 (2005)
  116. Bluher, Diabetes, 55, 3053 (2006)
  117. Després, New Engl. J. Med., 353, 2121 (2005)
  118. Gaal, Lancet, 365, 1389 (2005)
  119. Pi-Sunyer, J. Am. Med. Assoc., 295, 761 (2006)
  120. Scheen, Lancet, 368, 1660 (2006)
  121. A. Iranmanesh, J. Rosenstock, P. Hollander, 19th World Diabetes Congress, December 2–7, 2006, Cape Town, South Africa.
  122. Hungund, J. Neurochem., 84, 698 (2003)
  123. Cheer, J Neurosci., 24, 4393 (2004)
  124. Solinas, J. Neurochem., 98, 408 (2006)
  125. Maldonado, Trends Neurosci., 29, 225 (2006)
  126. O'Brien, Pharmacol. Ther., 108, 18 (2005)
  127. Sanchis-Segura, Addict. Biol., 11, 2 (2006)
  128. Vries, Trends Pharmacol. Sci., 26, 420 (2005)
  129. Foll, J. Pharmacol. Exp. Ther., 312, 875 (2005)
  130. Castane, Neuropharmacology, 43, 857 (2002)
  131. Wang, Proc. Natl. Acad. Sci. U.S.A, 100, 1393 (2003)
  132. Vries, Behav. Brain Res., 161, 164 (2005)
  133. Benoit, Psychopharmacology, 181, 722 (2005)
  134. Caggiula, Psychopharmacology, 163, 230 (2002)
  135. Caggiula, Pharmacol. Biochem. Behav., 70, 515 (2001)
  136. Caggiula, Physiol. Behav., 77, 683 (2002)
  137. Bevins, Behav. Cogn. Neurosci. Rev., 3, 143 (2004)
  138. Freedland, Alcoholism Clin. Exper. Res., 25, 277 (2001)
  139. Poncelet Martine, Maruani Jeanne, Calassi Roselyne, Soubrié Philippe, Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice, 10.1016/s0304-3940(03)00397-5
  140. Serra, Eur. J. Pharmacol., 430, 369 (2001)
  141. Serra, Eur. J. Pharmacol., 443, 95 (2002)
  142. Racz, J Neurosci., 23, 2453 (2003)
  143. Soria, Neuropsychopharmacology, 30, 1670 (2005)
  144. Navarro, NeuroReport, 9, 3397 (1998)
  145. Mas-Nieto, Br. J. Pharmacol., 132, 1809 (2001)
  146. Rubino, Life Sci., 66, 2213 (2000)
  147. Chiara, Proc. Natl. Acad. Sci. U.S.A, 85, 5274 (1988)
  148. Phillips, Nature, 422, 614 (2003)
  149. Roitman, J. Neurosci., 24, 1265 (2004)
  150. Cheer, J. Neurosci., 27, 791 (2007)
  151. Gelfand, Expert Opin. Investig. Drugs, 15, 307 (2006)
  152. European Public Assessment Report (EPAR) on Rimonabant, European Medicines Agency, 2006: see http://www.emea.eu.int/humandocs/Humans/EPAR/acomplia/acomplia.htm.
  153. L. Dale, R. Anthenelli, Proceeding of the Annual Scientific Session of the American College of Cardiology, March 7–10, 2004, New Orleans, Louisiana.
  154. Julien, Gastroenterology, 128, 742 (2005)
  155. Hezode, Hepatology, 42, 63 (2005)
  156. Batkai, Nat. Med., 7, 827 (2001)
  157. Ros, Gastroenterology, 122, 85 (2002)
  158. Moezi, Br. J. Pharmacol., 149, 898 (2006)
  159. Avraham, Neurobiol. Dis., 21, 237 (2006)
  160. Portier, J. Pharmacol. Exp. Ther., 288, 582 (1999)
  161. Bouaboula, J. Biol. Chem., 274, 20397 (1999)
  162. Salo, J. Med. Chem., 48, 7166 (2005)
  163. Muccioli, Curr. Med. Chem., 12, 1361 (2005)
  164. Mussinu, Bioorg. Med. Chem., 11, 251 (2003)
  165. Murineddu, J. Med. Chem., 49, 7502 (2006)
  166. Reggio, Life Sci., 56, 2025 (1995)
  167. Ross, Br. J. Pharmacol., 126, 665 (1999)
  168. Govaerts, Eur. J. Pharmacol., 495, 43 (2004)
  169. , , to Japan Tobacco, WO2000040562, 2000.
  170. Iwamura, J. Pharmacol. Exp. Ther., 296, 420 (2001)
  171. Raitio, J. Med. Chem., 49, 2022 (2006)
  172. Lavey, Bioorg. Med. Chem. Lett., 15, 783 (2005)
  173. Shankar, Bioorg. Med. Chem. Lett., 15, 4417 (2005)
  174. Gonsiorek, J. Biol. Chem., 281, 28143 (2006)
  175. Jr., Bioorg. Med. Chem. Lett., 12, 2399 (2002)
  176. Wrobleski, J. Med. Chem., 46, 2110 (2003)
  177. Stern, J. Med. Chem., 49, 70 (2006)
  178. Manera, J. Med. Chem., 49, 5947 (2006)
  179. Huffman, Curr. Med. Chem., 12, 1395 (2005)
  180. Galiegue, Eur. J. Biochem., 232, 54 (1995)
  181. Howlett, Pharmacol. Rev., 54, 161 (2002)
  182. Benito, J. Neurosci., 23, 11136 (2003)
  183. Sickle, Science, 310, 329 (2005)
  184. Massi, Eur. J. Pharmacol., 387, 343 (2000)
  185. Jorda, Blood, 99, 2786 (2002)
  186. Kishimoto, J. Biol. Chem., 278, 24469 (2003)
  187. Franklin, Eur. J. Pharmacol., 474, 195 (2003)
  188. Kishimoto, J. Biochem., 135, 517 (2004)
  189. McCoy, J. Pharmacol. Exp. Ther., 289, 1620 (1999)
  190. Idris, Nat. Med., 11, 774 (2005)
  191. Ofek, Proc. Natl. Acad. Sci. U.S.A, 103, 696 (2006)
  192. Oka, J. Biol. Chem., 280, 18488 (2005)
  193. Ueda, Eur. J. Pharmacol., 520, 164 (2005)
  194. Klein, J. Leukoc. Biol., 74, 486 (2003)
  195. Lunn, Expert Opin. Ther. Targets, 10, 653 (2006)
  196. Massi, Curr. Pharm. Des., 12, 3135 (2006)
  197. Lunn, J. Pharmacol. Exp. Ther., 316, 780 (2006)
  198. Ueda, Life Sci., 80, 414 (2007)
  199. Oka S., Wakui J., Ikeda S., Yanagimoto S., Kishimoto S., Gokoh M., Nasui M., Sugiura T., Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice, 10.4049/jimmunol.177.12.8796
Bibliographic reference Muccioli, Giulio. Blocking the cannabinoid receptors: Drug candidates and therapeutic promises. In: Chemistry & Biodiversity, Vol. 4, no. 8, p. 1805-1827 (2007)
Permanent URL http://hdl.handle.net/2078.1/37358